Type I Interferons Modulate CD8+ T Cell Immunity to mRNA Vaccines

Trends Mol Med. 2017 Mar;23(3):216-226. doi: 10.1016/j.molmed.2017.01.006. Epub 2017 Feb 7.

Abstract

mRNA vaccines have emerged as potent tools to elicit antitumor T cell immunity. They are characterized by a strong induction of type I interferons (IFNs), potent inflammatory cytokines affecting T cell differentiation and survival. Recent reports have attributed opposing roles for type I IFNs in modulating CD8+ T cell immunity to mRNA vaccines, from profoundly stimulatory to strongly inhibitory. The mechanisms behind this duality are unclear. Disentangling the factors governing the beneficial or detrimental impact of type I IFNs on CD8+ T cell responses is vital to the design of mRNA vaccines of increased potency. In light of recent advancements regarding the complex role of type I IFNs in regulating CD8+ T cell immunity to infectious diseases, we posit that the dual outcome of type I IFNs on CD8+ T cell responses to mRNA vaccination is determined by the timing and intensity of type I IFN induction relative to T cell receptor (TCR) activation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes / immunology*
  • Dendritic Cells / immunology
  • Humans
  • Immunity, Cellular*
  • Immunity, Innate
  • Interferon Type I / immunology*
  • Lymphocyte Activation
  • RNA, Messenger / immunology*
  • Vaccines / immunology*

Substances

  • Interferon Type I
  • RNA, Messenger
  • Vaccines